"The trials are being carried out in the UK in conjunction with the British Government's Vaccine Development Task Force and involve the participation and immunization over the next four to six weeks of up to 10,000 people between the ages of 18 and 84 with and without comorbidities." said in a press release from the company.
The trials will validate the effectiveness, safety and immunogenicity of the company's NVX-CoV2373 vaccine.
Earlier, Johnson & Johnson began the final phase of trials of a coronavirus vaccine.
US President Donald Trump said the country intends to begin distributing the US coronavirus vaccine in October.